|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IFT22 |
Gene summary for IFT22 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IFT22 | Gene ID | 64792 |
| Gene name | intraflagellar transport 22 | |
| Gene Alias | FAP9 | |
| Cytomap | 7q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q9H7X7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 64792 | IFT22 | LZE7T | Human | Esophagus | ESCC | 1.01e-03 | 3.31e-01 | 0.0667 |
| 64792 | IFT22 | LZE22T | Human | Esophagus | ESCC | 5.08e-04 | 4.31e-01 | 0.068 |
| 64792 | IFT22 | LZE24T | Human | Esophagus | ESCC | 2.86e-16 | 7.04e-01 | 0.0596 |
| 64792 | IFT22 | LZE6T | Human | Esophagus | ESCC | 3.84e-06 | 2.99e-01 | 0.0845 |
| 64792 | IFT22 | P1T-E | Human | Esophagus | ESCC | 3.80e-06 | 4.11e-01 | 0.0875 |
| 64792 | IFT22 | P2T-E | Human | Esophagus | ESCC | 1.11e-99 | 1.70e+00 | 0.1177 |
| 64792 | IFT22 | P4T-E | Human | Esophagus | ESCC | 1.07e-24 | 6.58e-01 | 0.1323 |
| 64792 | IFT22 | P5T-E | Human | Esophagus | ESCC | 7.42e-21 | 4.39e-01 | 0.1327 |
| 64792 | IFT22 | P8T-E | Human | Esophagus | ESCC | 1.23e-21 | 4.34e-01 | 0.0889 |
| 64792 | IFT22 | P9T-E | Human | Esophagus | ESCC | 1.97e-12 | 4.11e-01 | 0.1131 |
| 64792 | IFT22 | P10T-E | Human | Esophagus | ESCC | 7.50e-29 | 5.43e-01 | 0.116 |
| 64792 | IFT22 | P11T-E | Human | Esophagus | ESCC | 1.42e-12 | 5.24e-01 | 0.1426 |
| 64792 | IFT22 | P12T-E | Human | Esophagus | ESCC | 8.83e-31 | 5.94e-01 | 0.1122 |
| 64792 | IFT22 | P15T-E | Human | Esophagus | ESCC | 4.54e-40 | 9.63e-01 | 0.1149 |
| 64792 | IFT22 | P16T-E | Human | Esophagus | ESCC | 1.61e-53 | 9.90e-01 | 0.1153 |
| 64792 | IFT22 | P17T-E | Human | Esophagus | ESCC | 8.05e-24 | 1.05e+00 | 0.1278 |
| 64792 | IFT22 | P19T-E | Human | Esophagus | ESCC | 3.33e-09 | 7.29e-01 | 0.1662 |
| 64792 | IFT22 | P20T-E | Human | Esophagus | ESCC | 4.10e-48 | 1.07e+00 | 0.1124 |
| 64792 | IFT22 | P21T-E | Human | Esophagus | ESCC | 7.80e-59 | 1.12e+00 | 0.1617 |
| 64792 | IFT22 | P22T-E | Human | Esophagus | ESCC | 9.36e-39 | 7.32e-01 | 0.1236 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IFT22 | SNV | Missense_Mutation | rs190539623 | c.287N>A | p.Arg96Gln | p.R96Q | Q9H7X7 | protein_coding | tolerated(0.57) | benign(0.009) | TCGA-AR-A1AY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Doxorubicin | SD |
| IFT22 | SNV | Missense_Mutation | novel | c.460N>G | p.Pro154Ala | p.P154A | Q9H7X7 | protein_coding | tolerated(0.23) | benign(0.174) | TCGA-B6-A0X5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| IFT22 | insertion | Nonsense_Mutation | novel | c.456_457insTTCCTGGCCCCAGAACTTCCCAAAGACCTGTAAAATGGAGG | p.Asp153PhefsTer11 | p.D153Ffs*11 | Q9H7X7 | protein_coding | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR | ||
| IFT22 | SNV | Missense_Mutation | c.354N>A | p.Met118Ile | p.M118I | Q9H7X7 | protein_coding | tolerated(0.31) | benign(0.01) | TCGA-JW-A69B-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| IFT22 | SNV | Missense_Mutation | novel | c.28N>T | p.Gly10Trp | p.G10W | Q9H7X7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| IFT22 | SNV | Missense_Mutation | rs375452848 | c.199N>A | p.Asp67Asn | p.D67N | Q9H7X7 | protein_coding | tolerated(0.09) | benign(0.176) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| IFT22 | SNV | Missense_Mutation | rs190539623 | c.287G>A | p.Arg96Gln | p.R96Q | Q9H7X7 | protein_coding | tolerated(0.57) | benign(0.009) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| IFT22 | SNV | Missense_Mutation | c.400C>A | p.Leu134Met | p.L134M | Q9H7X7 | protein_coding | tolerated(0.11) | benign(0.332) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| IFT22 | SNV | Missense_Mutation | novel | c.158A>T | p.Lys53Ile | p.K53I | Q9H7X7 | protein_coding | deleterious(0) | benign(0.372) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
| IFT22 | SNV | Missense_Mutation | rs370329389 | c.259N>A | p.Val87Ile | p.V87I | Q9H7X7 | protein_coding | tolerated(0.49) | benign(0.065) | TCGA-B5-A0K9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |